title: The role of targeted therapy for gastrointestinal tumors.
abstract: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
authors: Oncology Department, University Hospital Antwerp UZA, University of Antwerp, Wilrijkstraat 10, 2650, Antwerp, Belgium.
authors: Christian
authors: C
authors: Rolfo
authors: Giuseppe
authors: G
authors: Bronte
authors: Giovanni
authors: G
authors: Sortino
authors: Konstantinos
authors: K
authors: Papadimitriou
authors: Francesco
authors: F
authors: Passiglia
authors: Eugenio
authors: E
authors: Fiorentino
authors: Ghada
authors: G
authors: Marogy
authors: Antonio
authors: A
authors: Russo
authors: Marc
authors: M
authors: Peeters
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000502:physiology; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D042461:Vascular Endothelial Growth Factor A
keywords: colorectal cancer; gastric cancer; gastrointestinal tumors; hepatocellular carcinoma; neuroendocrine tumors; targeted therapy